Don Roberts, MD
Gastroenterology · Moultrie, GANPI 1780755918
Payments from drug & device makers
Across 516 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$959
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$897
- Takeda Pharmaceuticals U.S.A., Inc.$626
- Daiichi Sankyo Inc.$462
- Nestle Healthcare Nutrition Inc.$378
- plus $2K from 27 others
What the payments were for
- Consulting fees$260%
- Food & beverage$8,17197%
- Education$2092%
- Gifts$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 179 | $2,628 |
| Johnson & Johnson | 48 | $959 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $897 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $626 |
| Daiichi Sankyo Inc. | 22 | $462 |
| Nestle Healthcare Nutrition Inc. | 18 | $378 |
| Ironwood Pharmaceuticals, Inc | 20 | $307 |
| Madrigal Pharmaceuticals | 12 | $278 |
| Ferring Pharmaceuticals Inc. | 16 | $224 |
| Evoke Pharma, Inc. | 12 | $205 |
| Intercept Pharmaceuticals, Inc. | 11 | $198 |
| Regeneron Healthcare Solutions, Inc. | 10 | $196 |
| Sanofi | 6 | $168 |
| Pfizer | 10 | $155 |
| Gilead | 5 | $115 |
| Braintree Laboratories, Inc. | 6 | $91 |
| Redhill Biopharma Inc. | 6 | $91 |
| Boston Scientific | 4 | $63 |
| Vivus LLC | 3 | $54 |
| Boehringer Ingelheim | 3 | $45 |
| Alfasigma USA, Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 5 | $30 |
| Merck | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Concordia Pharmaceuticals Inc. | 2 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Echosens North America, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| UCB, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Mauna Kea Technologies, Inc. | 2 | $12 |
| Dova Pharmaceuticals | 1 | $11 |
How this compares
$8,418 in reported general payments places this provider in the 70th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 26 | $126,635 |
| CreonLipase/Protease/Amylase | 30 | $124,713 |
| OcalivaObeticholic Acid | 12 | $106,216 |
| XifaxanRifaximin | 26 | $86,264 |
| LinzessLinaclotide | 78 | $52,712 |
| ViberziEluxadoline | 19 | $30,658 |
| GimotiMetoclopramide Hcl | 13 | $25,963 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 144 | $24,861 |
| Dexlansoprazole DrDexlansoprazole | 59 | $15,310 |
| MotegrityPrucalopride Succinate | 13 | $14,866 |
| MovantikNaloxegol Oxalate | 22 | $9,157 |
| DexilantDexlansoprazole | 24 | $9,034 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 122 | $8,052 |
| Dicyclomine Hcl | 275 | $4,506 |
| Lubiprostone | 23 | $3,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Viberzi | $2,628 | $208,082127 claims |
| Aimmune Therapeutics, Inc.Zenpep | $23 | $126,63526 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $198 | $106,21612 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $897 | $86,26426 claims |
| Evoke Pharma, Inc.Gimoti | $205 | $25,96313 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $224 | $24,861144 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $626 | $23,90037 claims |
| Redhill Biopharma Inc.Movantik | $91 | $9,15722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Moultrie
- Douglas WolfAtlanta$6.4M
- Aasim SheikhMarietta$6M
- Shahriar SedghiMacon$5.4M
- Jeffrey WilliamsAthens$2.5M
- Michael GalambosAtlanta$1.8M
- Nitin GuptaAtlanta$1.7M
- Bruce SalzbergSuwanee$1.4M
- Heba IskandarAtlanta$978K
- David RausherDecatur$907K
- Florence Hosseini AsliniaHiram$885K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.